TLPH - AcelRx Pharmaceuticals Q1 2025 Earnings Preview
2025-05-13 17:35:20 ET
More on AcelRx Pharmaceuticals
- Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
- Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
- AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09
- Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals
- Historical earnings data for AcelRx Pharmaceuticals